CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
Changhoon Yoo, Boram Han, Hyeong Su Kim, Kyu-pyo Kim, Deokhoon Kim, Jae Ho Jeong, Jae-Lyun Lee, Tae Won Kim, Jung Han Kim, Dae Ro Choi, Hong Il Ha, Jinwon Seo, Heung-Moon Chang, Baek-Yeol Ryoo, Dae Young Zang
Cancer Research and Treatment. 2018;50(4):1324-1330.   Published online 2018 January 8    DOI: https://doi.org/10.4143/crt.2017.526

Excel Download

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
Cancer Research and Treatment. 2018;50(4):1324-1330   Crossref logo
Link1 Link2 Link3

627 POSTER UFT/LV combined with oxaliplatin (TEGAFOX) or with irinotecan (TEGAFIRI) as first-line treatment for metastatic colorectal cancer patients (pts). results of a randomized phase II I.T.M.O. study
European Journal of Cancer Supplements. 2005;3(2):177   Crossref logo
Link1 Link2

S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
British Journal of Cancer. 2013;109(6):1420-1427   Crossref logo
Link1 Link2 Link3

703 PUBLICATION Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
European Journal of Cancer Supplements. 2005;3(2):199-200   Crossref logo
Link1 Link2

3529 POSTER A phase II trial of oxaliplatin with high-dose of 5-fluorouracil and leucovorin in the first-line treatment of inoperable, locally advanced or metastatic biliary tract cancer
European Journal of Cancer Supplements. 2007;5(4):268   Crossref logo
Link1 Link2

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study
BMC Cancer. 2010;10(1):   Crossref logo
Link1 Link2 Link3

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
British Journal of Cancer. 2009;100(11):1720-1724   Crossref logo
Link1 Link2 Link3

Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study
Clinical Epidemiology. 2015;295   Crossref logo
Link1

Irinotecan (CPT-11) plus oxaliplatin (LOHP) plus infusional 5-fluorouracil (5-FU) and leukovorin (LV) as first line treatment for metastatic colorectal cancer (MCC): A phase II trial
European Journal of Cancer. 2001;37:S307   Crossref logo
Link1 Link2

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
Cancer Medicine. 2015;4(10):1505-1513   Crossref logo
Link1

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.